XTL Biopharmaceuticals Faces Nasdaq Listing Compliance Issues

viernes, 23 de enero de 2026, 4:29 pm ET1 min de lectura
XTLB--

XTL Biopharmaceuticals received a notification from Nasdaq stating that the company is not in compliance with the minimum $2.5M stockholders' equity requirement. The decision was based on a $47,000 stockholders' equity deficit in the company's December 2025 Form 6-K. XTL is evaluating options to regain compliance and intends to do so within Nasdaq's required timeframe.

XTL Biopharmaceuticals Faces Nasdaq Listing Compliance Issues

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios